Menu
Curie Logo
Donate
  • Home

Clinical trials - page 2

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Paris
    DF1001-001
    A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

    EMANUELA ROMANO

  • Paris
    GSK 219451 - POPSTAR
    Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR).

    AMAURY LERUSTE

  • Paris, Saint-Cloud
    REVCCI
    Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia

    ABDELMALEK GHIMOUZ

  • Breast cancer
    Paris, Saint-Cloud
    HEROES
    De-escalation of medical treatments in HER2-positive metastatic breast cancer in case of long-term persistent response and undetectable minimal residual disease assessed by circulating tumor DNA.

    DIANA BELLO ROUFAI

  • Paris
    DF6215-001
    A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

    EMANUELA ROMANO

  • Paris
    EUonQoL
    Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe · Developing the toolkit: Patient preferences and priorities for quality of life domains across the cancer care continuum.

  • Paris
    MK3475-522 (Keynote-522)
    A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    MARIE PAULE SABLIN

  • Paris, Saint-Cloud
    POP-ART
    A Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.

    FRANCOIS-CLEMENT BIDARD

  • ENT/Head and Neck Cancers
    Paris
    219885 GALAXIES H&N-202
    A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

    CHRISTOPHE LE TOURNEAU

  • Paris
    BGB-A317-A3055-101
    A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Childhood and adolescent cancers
    Paris
    I3Y-MC-JPEH
    A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

    ISABELLE AERTS GAJDOS

  • Cancers gynécologiques
    Paris, Saint-Cloud
    COLIBRI- 2
    Phase·Ib/II, multicenter, open-label study evaluating BDC-1001, a HER2-targeted TLR7/8 agonist antibody-drug conjugate, as monotherapy and in combination with nivolumab in advanced HER2-expressing solid tumors.

    HELENE SALAUN

  • Sarcomas
    Paris
    TANGENT (SNX-301-020)
    A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.

    SOPHIE PIPERNO-NEUMANN

  • Lung cancer
    Paris
    COCOON
    A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.

    NICOLAS GIRARD

  • Sarcomas
    Paris
    TRUST
    Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)

    CLEMENT BONNET

  • Paris, Saint-Cloud
    PALLU
    A randomized comparative prospective multicenter study of the efficacy of a systematic referral to palliative care of patients who need for palliative care during an unscheduled visit in comprehensive anticancer centers.

    CAROLE BOULEUC-PARROT

  • Childhood and adolescent cancers
    Paris
    INFORM2 - NIVENT (IC 2018-07)
    INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies

    GUDRUN SCHLEIERMACHER

  • Thyroid cancer
    Saint-Cloud
    INTERMEDIATE-01
    Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy

    CAPUCINE RICHARD

  • Saint-Cloud
    IONESCO (IFCT-1601)
    A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer.

    MARIE ANGE MASSIANI

  • Saint-Cloud
    IROCAS - PRODIGE 52
    A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting

  • Paris
    LCB-1801-001
    A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF NI-1801, A BISPECIFIC MESOTHELIN x CD47 ENGAGING ANTIBODY,IN PATIENTS WITH MESOTHELIN EXPRESSING SOLID CANCERS.

    EMANUELA ROMANO

  • Lung cancer
    Paris
    Lunar- 2
    LUNAR-2: a pivotal, randomized, open-label trial of Tumor Treating Fields (TTFields, 150 kHz) combined with pembrolizumab and platinum-based chemotherapy in the treatment of metastatic non·small cell lung cancer.

    NICOLAS GIRARD

  • Saint-Cloud
    M20-621
    A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL).

    CLEMENTINE SARKOZY

  • Saint-Cloud
    MAPAM-01
    Therapeutic Nipple Areola Skin-sparing Mastectomy.

    EUGENIE GUILLOT

  • Saint-Cloud
    MCLA-128-CL01
    A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

  • Saint-Cloud
    MCLA-128-CL02
    Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

    FRANCOIS-CLEMENT BIDARD

  • Paris
    MCLA-158-CL01
    Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.

    EDITH BORCOMAN

  • Paris
    MCLA-158-CL02
    A phase 3, open-label, randomized, controlled study aimed at evaluating the efficacy and safety of petosemtamab compared to the investigator's choice of monotherapy in previously treated patients with metastatic/recurring, incurable head and neck squamous cell carcinoma

    EDITH BORCOMAN

  • ENT/Head and Neck Cancers
    Paris
    MCLA-158-CL03/LiGeR-HN1
    A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

    CHRISTOPHE LE TOURNEAU

  • Thyroid cancer
    Saint-Cloud
    MIBI-THYR
    Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology.

    CAPUCINE RICHARD

<
1 2...7
>